Antifungal therapeutic drug monitoring is a critical component of individualized, precision treatment for fungal infections and for antifungal stewardship. Antifungal therapeutic drug monitoring can help improve outcomes through minimizing toxicity associated with supratherapeutic drug levels and prevent treatment failure from subtherapeutic levels. Also, in vitro studies have shown that suboptimal drug levels can lead to antifungal resistance, supporting therapeutic drug monitoring's potential role in preventing the emergence of antifungal-resistant organisms. This episode podcast, we discuss outcome data when antifungal TDM is used, role of antifungal TDM with isavuconazole and echinocandins, TDM in outpatient settings, and other controversies. We will also highlight the recent antifungal TDM insights published by SIDP.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.